Vera Therapeutics/$VERA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Vera Therapeutics
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
Ticker
$VERA
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
152
ISIN
US92337R1014
Website
VERA Metrics
BasicAdvanced
$1.5B
-
-$3.00
1.13
-
Price and volume
Market cap
$1.5B
Beta
1.13
52-week high
$49.23
52-week low
$18.53
Average daily volume
2.4M
Financial strength
Current ratio
27.682
Quick ratio
27.104
Long term debt to equity
9.958
Total debt to equity
10.18
Interest coverage (TTM)
-25.73%
Profitability
EBITDA (TTM)
-193.126
Effective tax rate (TTM)
-0.00%
Management effectiveness
Return on assets (TTM)
-23.46%
Return on equity (TTM)
-39.49%
Valuation
Price to book
2.83
Price to tangible book (TTM)
2.83
Price to free cash flow (TTM)
-8.894
Free cash flow yield (TTM)
-11.24%
Free cash flow per share (TTM)
-267.37%
Growth
Earnings per share change (TTM)
46.40%
3-year earnings per share growth (CAGR)
8.95%
What the Analysts think about VERA
Analyst ratings (Buy, Hold, Sell) for Vera Therapeutics stock.
Bulls say / Bears say
Vera Therapeutics' lead product, atacicept, demonstrated a 42% reduction in proteinuria compared to placebo in Phase 3 trials for IgA nephropathy, indicating strong efficacy. (Benzinga)
Analysts have raised their price targets for Vera Therapeutics, with Guggenheim increasing its target from $56 to $64, reflecting confidence in the company's growth prospects. (Defense World)
Vera Therapeutics secured an exclusive license from Stanford University for VT-109, a next-generation fusion protein targeting BAFF and APRIL, expanding its pipeline in B cell-mediated diseases. (Benzinga)
Vera Therapeutics announced a $300 million public offering of Class A common stock, which could lead to shareholder dilution. (Nasdaq)
Insider selling activity, including the sale of 15,000 shares by Director Beth C. Seidenberg, may raise concerns about internal confidence in the company's future performance. (ETF Daily News)
Despite positive trial results, the stock experienced a significant drop of over 34% in October 2023, indicating potential volatility and investor uncertainty. (Yahoo Finance)
Data summarised monthly by Lightyear AI. Last updated on 12 Jul 2025.
VERA Financial Performance
Revenues and expenses
VERA Earnings Performance
Company profitability
VERA News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Vera Therapeutics stock?
Vera Therapeutics (VERA) has a market cap of $1.5B as of July 15, 2025.
What is the P/E ratio for Vera Therapeutics stock?
The price to earnings (P/E) ratio for Vera Therapeutics (VERA) stock is 0 as of July 15, 2025.
Does Vera Therapeutics stock pay dividends?
No, Vera Therapeutics (VERA) stock does not pay dividends to its shareholders as of July 15, 2025.
When is the next Vera Therapeutics dividend payment date?
Vera Therapeutics (VERA) stock does not pay dividends to its shareholders.
What is the beta indicator for Vera Therapeutics?
Vera Therapeutics (VERA) has a beta rating of 1.13. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.